TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has successfully completed the Maintenance and Transition phases of Study VRX-RET-E22-302 for the treatment of partial-onset seizures~* Patient is expected to benefit from participation in the study in the opinion of the Investigator.~Exclusion Criteria:~* Patient meets any of the withdrawal criteria in the previous VRX-RET-E22-302 study or is experiencing an ongoing serious adverse event.~* Patient is receiving any investigational drug or using any experimental device in addition to Retigabine for treatment of epilepsy or any other medical condition.~* Patient has any other condition that would prevent compliance with the study procedures or proper reporting of adverse events.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Retigabine (INN), Ezogabine (USAN) (Type: EXPERIMENTAL): Retigabine (Ezogabine): all subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA \>1,000 copies/ml)~* Gestational age higher than 28 weeks~* Age equal or higher than 15 years~* HIV-1 plasma viral load ≥ 1,000 copies of HIV-1 RNA/ml~Exclusion Criteria:~* Age lower than 15 years~* Undetectable plasma viral load at screening~* Previous use of RAL

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Raltegravir (Type: EXPERIMENTAL): Use of Raltegravir plus backbone treatment for pregnant women
- Lopinavir/Ritonavir (Type: ACTIVE_COMPARATOR): Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male and female patients between 10 and 20 years of age~* Insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at time of screening~* Fasting C-peptide level at time of screening above 0.1 nmol/L~* Elevated GAD65 antibodies (GADA) at time of screening~Main Exclusion Criteria:~* Treatment with immunosuppressants or any anti-diabetic medications other than insulin~* A history of certain diseases or conditions (e.g. anemia, HIV, hepatitis, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)~* Treatment with any vaccine within 1 month prior to planned first Diamyd dose or planned treatment with vaccine up to 2 months after the last injection with Diamyd, excluding the influenza vaccine~* Participation in other clinical trials with a new chemical entity within the previous 3 months~* Pregnancy or planned pregnancy within 1 year after the last Diamyd dose~* Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on Days 90 and 270.
- B (Type: ACTIVE_COMPARATOR): This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on Days 90 and 270.
- C (Type: PLACEBO_COMPARATOR): This arm will receive 4 injections of placebo, 1 each on Days 1, 30, 90, and 270.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Weekly Versus no Routine Ventilator Circuit Changes in NICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All neonates who admitted at neonatal intensive care unit (NICU) and required ventilator support with both intubated at time of neonatal resuscitation and within the NICU as indicated~Exclusion Criteria:~* Patient was extubated or died within 2 calendar days of endotracheal intubation~* Pneumonia was diagnosed before intubation~* Outborn who was intubated before referred~* Parents declined to participate~* Incompatibility of disposable circuits and ventilator~* Chromosome abnormality or moribund

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Weekly ventilator circuit change (Type: EXPERIMENTAL): Ventilator circuit change every 7 days until extubation
- No routine ventilator circuit change (Type: ACTIVE_COMPARATOR): No routine ventilator circuit change until soiling or malfunction or extubation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed Stages iB-iiiB squamous cell carcinoma of the cervix~Exclusion Criteria:~* Evidence of ovarian involvement on MRI~* Evidence of uterine involvement on MRI~* Evidence of distant mets on MRI

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Laparoscopic Ovarian Transposition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biomarker Identification for Bladder Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥18 years old.~* Patients suspected, clinically diagnosed, or histologically diagnosed bladder cancer.~* Patients undergoing cystoscopy without cancer suspicion.~* Ability to give an informed consent.~Exclusion Criteria:~* Patients receiving concurrent therapy for a second malignancy.~* \< 18 years old.~* Inability to give an informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bladder Cancer Patients (Type: None): Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Biopsy-confirmed diagnosis of 1 of the following:~  * Mild to severe dysplasia~ * Carcinoma in situ (CIS) of the oral cavity~    * Carcinoma must be less than 3mm thick~ * Stage I (T1) squamous cell carcinoma of the oral cavity~* Recurrent or primary disease~* No T2 or greater squamous cell carcinoma, exophytic CIS, or dysplasia lesions~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Total bilirubin ≤ 2.0 mg/dL~* Creatinine ≤ 2.0 mg/dL~* Alkaline phosphatase ≤ 3 times the upper limit of normal (ULN)~* SGOT ≤ 3 times ULN~* Not pregnant~* Fertile patients must use effective contraception~* No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds~PRIOR CONCURRENT THERAPY:~* Prior therapy of any type allowed~* More than 4 weeks since prior and no concurrent chemotherapy or radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (PDT) (Type: EXPERIMENTAL): Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light treatment to the tumor bed on day 2. Treatment may repeat every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Good Intentions Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index from 18-45 kg/m2~Exclusion Criteria:~* have any medical conditions that prevent participant from safely taking part in physical activity~* currently a smoker~* are pregnant, breastfeeding, or plan to become pregnant~* have visited fitness centers more than eight times in the past two months~* exercise outside of fitness centers more than once a week for one hour at a time in the past month~* do not engage in more than 14 hours a week of screen-based activities~* do not have a primarily sedentary job

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Exercise-only intervention (Type: EXPERIMENTAL): Participants will receive information regarding the health benefits of regular aerobic and resistance training exercise and current physical activity guidelines for adults.
- Control intervention (Type: SHAM_COMPARATOR): Participants will receive information regarding the health risks of chronic stress as well as suggested methods to reduce stress.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of EnChroma Use in the Emergency Department Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65~* Red-Green color deficiency~Exclusion Criteria:~* Achromatopsia~* Cataracts~* Glaucoma~* Legal blindness~* Macular degeneration~* Retinitis Pigmentosa

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EnChroma glasses (Type: EXPERIMENTAL): EnChroma products improve brightness and color purity of primary colors for CVD people. Each participant with CVD will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Subject is currently hospitalized and is mechanically ventilated endotracheally (i.e., orotracheal or nasotracheal) and, in the Investigator's opinion, will require ongoing ventilator support for at least 48 hours;~Exclusion Criteria:~* Subject has a chest X-ray or thoracic computed tomography (CT) scan that is definitive for a diagnosis of pneumonia~* Subject has a known and documented ETA culture showing heavy colonization with a -Gram-negative organism at enrollment or at any time during the Screening period;~* Significant Neutropenia~* Severe non-pulmonary source of infection.~* Subjects with a known history or current (suspected) diagnosis of cytokine release syndrome associated with the administration of peptides, proteins, and/or antibodies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered as 2 separate intravenous (IV) infusions
- ASN100 (Type: EXPERIMENTAL): ASN100 administered as 2 separate intravenous (IV) infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* condition after febrile seizure~* age 12 months to 5 years~* written informed consent~Exclusion Criteria:~* severe other organic disease~* meningitis as possible cause for the cerebral seizure~* neurologic disease or cerebral dysplasia~* cerebrale seizures without fever in the medical history~* hypersynchronic eeg activity~* disorder of the respiratory tract (Asthma e.g.)

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Verum (Type: EXPERIMENTAL): Verum arm receiving Carbogen
- Placebo (Type: PLACEBO_COMPARATOR): Placebo arm receiving oxygen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with cT2-T3/N0-N1-M1a-M1b(lymph node metastasis only) esophageal squamous cell and adenocarcinoma who have potentially resectable disease.~* Karnofsky performance status greater than or equal to 80%.~* Pulmonary and cardiac function must be acceptable for surgery according to institutional standards.~* Acceptable hepatic, renal and bone marrow function.~* Age 18 or older.~* Patients may receive preoperative chemotherapy and/or radiation therapy as part of their clinical care.~Exclusion Criteria:~* Patients with clearly unresectable or metastatic esophageal cancer or clinical stage I esophageal cancer.~* Significant psychiatric illness that would interfere with patient compliance.~* Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment.~* Patients with a significant history of unstable cardiovascular disease (e.g., inadequately controlled hypertension, or angina; myocardial infarction within the previous 6 months; ventricular cardiac arrhythmias requiring medication; congestive heart failure that in the opinion of the treating physician should preclude the patient from protocol treatment.~* Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or interstitial pneumonia or interstitial fibrosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): En bloc esophagectomy is performed through a transthoracic approach by removing the tumor-bearing esophagus, the pericardium anteriorly, both pleural surfaces laterally, as well as the thoracic duct and all other lymphoareolar tissue wedged posteriorly between the esophagus and the spine, and en-bloc resection of all nodal groups in the middle and lower mediastinum as well as the upper abdomen.
- B (Type: ACTIVE_COMPARATOR): Transhiatal esophagectomy is performed through an abdominal incision and a neck incision. The stomach is mobilized, and the left gastric vessels are transected at its origin. Celiac lymph nodes are dissected, and the intrathoracic esophagus is dissected bluntly through the hiatus and through the neck. The cervical esophagus is divided at the level of the neck. After the esophagogastrectomy is performed, a gastric tube is created. An esophagogastrostomy is then performed in the neck. If a transthoracic approach is used, dissection will be as described for the transhiatal approach.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mixed-lineage leukemia (MLL) gene rearranged Acute Lymphoblastic Leukemia (ALL), that does not respond to treatment or has relapsed from prior treatment; or FLT3 mutated Acute Myeloid Leukemia (AML) that does not respond to a second treatment or has relapsed from 2 prior treatments~* Normal organ function, and chest x-ray~* Expected survival greater than 8 weeks~* Can care for most of personal needs and perform at least minimum activity~Exclusion Criteria:~* Patients with symptomatic leukemic central nervous system involvement or isolated extramedullary leukemia~* Patients must not have received other treatments for leukemia within a predefined time period, 72 hours for medications, 2 months for transplants~* Patients with heart function that is not normal~* Patients with HIV or hepatitis~* Patients with another severe disease or medical condition besides leukemia Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 30 mg/m^2 bid (Type: EXPERIMENTAL): Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m\^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m\^2 bid cohort was 60 mg/m\^2.
- 60 mg/m^2 bid (Type: EXPERIMENTAL): Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m\^2 bid through oral route. The total daily dose in 60 mg/m\^2 bid cohort was 120 mg/m\^2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Study of the Linear™ Hip

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have hip joint disease related to one or more of the following~  * osteoarthritis~ * rheumatoid arthritis~ * femoral fracture~ * correction of a functional deformity~ * avascular necrosis of the natural femoral head~* Skeletal maturity~* Patient is likely to be available for evaluation for the duration of the study~* Able and willing to sign the informed consent and follow study procedures~* Patient is not pregnant~* No infection present~* No known materials sensitivity~* Patient is over 18 years of age~Exclusion Criteria:~* Skeletal immaturity~* Infection or sepsis~* Insufficient bone quality that may affect the stability of the implant~* Muscular, neurologic or vascular deficiencies which compromise the affected extremity~* Alcoholism or other addictions~* Prisoners~* High levels of physical activity~* Patient is pregnant~* Loss of ligamentous structures~* Materials sensitivity~* Patient is under 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linear Hip (Type: None): Encore Linear Hip System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues